JP2021520208A5 - - Google Patents

Info

Publication number
JP2021520208A5
JP2021520208A5 JP2020554272A JP2020554272A JP2021520208A5 JP 2021520208 A5 JP2021520208 A5 JP 2021520208A5 JP 2020554272 A JP2020554272 A JP 2020554272A JP 2020554272 A JP2020554272 A JP 2020554272A JP 2021520208 A5 JP2021520208 A5 JP 2021520208A5
Authority
JP
Japan
Prior art keywords
hhla2
cancer
monoclonal antibody
antigen
subject
Prior art date
Application number
JP2020554272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520208A (ja
JP7429192B2 (ja
JPWO2019204057A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/026034 external-priority patent/WO2019204057A1/en
Publication of JP2021520208A publication Critical patent/JP2021520208A/ja
Publication of JP2021520208A5 publication Critical patent/JP2021520208A5/ja
Publication of JPWO2019204057A5 publication Critical patent/JPWO2019204057A5/ja
Priority to JP2024009992A priority Critical patent/JP2024032865A/ja
Application granted granted Critical
Publication of JP7429192B2 publication Critical patent/JP7429192B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554272A 2018-04-06 2019-04-05 Hhla2受容体としてのkir3dl3、抗hhla2抗体、およびその使用 Active JP7429192B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024009992A JP2024032865A (ja) 2018-04-06 2024-01-26 Hhla2受容体としてのkir3dl3、抗hhla2抗体、およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862654068P 2018-04-06 2018-04-06
US62,654,068 2018-04-06
PCT/US2019/026034 WO2019204057A1 (en) 2018-04-06 2019-04-05 Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024009992A Division JP2024032865A (ja) 2018-04-06 2024-01-26 Hhla2受容体としてのkir3dl3、抗hhla2抗体、およびその使用

Publications (4)

Publication Number Publication Date
JP2021520208A JP2021520208A (ja) 2021-08-19
JP2021520208A5 true JP2021520208A5 (https=) 2022-04-12
JPWO2019204057A5 JPWO2019204057A5 (https=) 2022-04-12
JP7429192B2 JP7429192B2 (ja) 2024-02-07

Family

ID=68239919

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020554272A Active JP7429192B2 (ja) 2018-04-06 2019-04-05 Hhla2受容体としてのkir3dl3、抗hhla2抗体、およびその使用
JP2024009992A Pending JP2024032865A (ja) 2018-04-06 2024-01-26 Hhla2受容体としてのkir3dl3、抗hhla2抗体、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024009992A Pending JP2024032865A (ja) 2018-04-06 2024-01-26 Hhla2受容体としてのkir3dl3、抗hhla2抗体、およびその使用

Country Status (13)

Country Link
US (2) US12103972B2 (https=)
EP (1) EP3773658A4 (https=)
JP (2) JP7429192B2 (https=)
KR (1) KR20210007959A (https=)
CN (1) CN112153977B (https=)
AU (2) AU2019257249B2 (https=)
BR (1) BR112020015999A2 (https=)
CA (1) CA3091859A1 (https=)
IL (1) IL276746B1 (https=)
MX (1) MX2020010094A (https=)
RU (1) RU2020136055A (https=)
SG (1) SG11202007898XA (https=)
WO (1) WO2019204057A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210007959A (ko) 2018-04-06 2021-01-20 다나-파버 캔서 인스티튜트 인크. Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도
EP4022637A2 (en) 2019-08-30 2022-07-06 Juno Therapeutics, Inc. Machine learning methods for classifying cells
CN114867493B (zh) 2019-10-04 2026-04-10 阿尔伯特爱因斯坦医学院 Kir3dl3是免疫系统的抑制性受体及其用途
JP7727662B2 (ja) * 2020-05-13 2025-08-21 ジュノー セラピューティクス インコーポレイテッド 臨床応答に関連する特徴量の特定方法およびその使用
CN112946268B (zh) * 2020-12-29 2022-12-27 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) Hhla2作为预后标记物在制备肝癌预后预测试剂盒中的应用
WO2022165258A1 (en) * 2021-01-28 2022-08-04 Nextpoint Therapeutics, Inc. Hhla2 binding agents with novel activity
CA3225139A1 (en) * 2021-07-01 2023-01-05 Albert Einstein College Of Medicine Compositions and methods for inhibiting the expression of tmigd2
CN113621068B (zh) * 2021-10-11 2022-01-07 上海恒润达生生物科技股份有限公司 一种特异性结合cd276的抗体或其抗原结合片段及其制备方法和应用
WO2023138579A1 (zh) * 2022-01-21 2023-07-27 和铂医药美国股份有限公司 抗b7-h7抗体或其抗原结合片段及制备方法和应用
WO2025040144A1 (zh) * 2023-08-23 2025-02-27 南京再明医药有限公司 B7-h7抗原结合分子及其应用
CN119841949A (zh) * 2023-10-17 2025-04-18 科辉智药(深圳)新药研究中心有限公司 一种抗人hhla2的纳米抗体及其应用
CN121005781A (zh) * 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 高亲和力b7h7抗体或其抗原结合片段及其用途
WO2025247197A1 (zh) * 2024-05-27 2025-12-04 杭州阿诺生物医药科技有限公司 一种多功能融合蛋白
CN120877013B (zh) * 2025-07-21 2026-01-30 湖南艾方生物科技有限公司 一种自适应的荧光免疫层定量检测特征提取方法及系统

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
US1984A (en) 1841-02-18 Machinery for trimming straw braid
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5230902A (en) 1988-04-29 1993-07-27 Immunotec Research Corporation Undenatured whey protein concentrate to improve active systemic humoral immune response
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4981844A (en) 1988-10-04 1991-01-01 University Of Cincinnati Method to improve immune response and resistance to infection following surgery by diet composition
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ(ユーケー)リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
ATE205542T1 (de) 1992-03-04 2001-09-15 Univ California Vergleichende genomhybridisierung
US5965362A (en) 1992-03-04 1999-10-12 The Regents Of The University Of California Comparative genomic hybridization (CGH)
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP4137996B2 (ja) 1992-05-06 2008-08-20 ジェン−プローブ・インコーポレイテッド 核酸配列増幅方法,組成物及びキット
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
DE4344726C2 (de) 1993-12-27 1997-09-25 Deutsches Krebsforsch Verfahren zum Nachweis von nicht balanciertem genetischen Material einer Spezies oder zum Nachweis der Genexpression in Zellen einer Spezies
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
JP2001522241A (ja) 1997-04-10 2001-11-13 ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ 診断方法および試薬
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
EP2392596A3 (en) 1999-12-28 2013-11-27 ESBATech, an Alcon Biomedical Research Unit LLC Intrabodies with defined framework that is stable in a reducing environment and applications thereof
US6618679B2 (en) 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
US20030104402A1 (en) 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
EP1378177A1 (en) 2002-07-02 2004-01-07 Hansen, John Erik Vitamin-containing system for stabilising the immune response of animals
CN1835679A (zh) 2003-06-16 2006-09-20 国立大学法人九州大学 人源免疫活性细胞的制备方法
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
AU2007285217B2 (en) 2006-08-14 2013-02-07 Forerunner Pharma Research Co., Ltd Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
WO2010101870A1 (en) 2009-03-03 2010-09-10 St. Jude Children's Research Hospital Compositions and methods for generating interleukin-35-induced regulatory t cells
ES2666152T3 (es) * 2009-08-13 2018-05-03 The Johns Hopkins University Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
CN102884085B (zh) 2010-04-09 2016-08-03 Aveo制药公司 抗erbb3抗体
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
BR112014000765A2 (pt) 2011-07-15 2017-06-13 Oncomed Pharm Inc agentes de ligação a rspo e seus usos
BR112014003315A2 (pt) 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
WO2013062134A1 (en) 2011-10-25 2013-05-02 Fumihiko Ishikawa Method for producing immune-system humanized mouse
EP2848633B1 (en) 2012-05-11 2019-02-06 Microbial Chemistry Research Foundation Anti-cxadr antibody
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014133728A2 (en) * 2013-03-01 2014-09-04 Albert Einstein College Of Medicine Of Yeshiva University Hhla2 as a novel inhibitor of human immune system and uses thereof
BR112015029395A2 (pt) 2013-05-24 2017-09-19 Medimmune Llc Anticorpos anti-b7-h5 e seus usos
WO2015187359A1 (en) 2014-06-04 2015-12-10 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway
AU2016353073A1 (en) 2015-11-10 2018-06-07 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
WO2018026969A2 (en) * 2016-08-03 2018-02-08 Achaogen, Inc. Plazomicin antibodies and methods of use
KR20210007959A (ko) 2018-04-06 2021-01-20 다나-파버 캔서 인스티튜트 인크. Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도
WO2024002990A1 (en) 2022-06-27 2024-01-04 Umicore Composite cathode material comprising ceramic oxide electrolyte, lithium electrode material and enhancing agent

Similar Documents

Publication Publication Date Title
JP2021520208A5 (https=)
RU2020136055A (ru) Kir3dl3 в качестве рецептора hhla2, анти-hhla2-антител и его использование
JP6823094B2 (ja) Ror1癌の治療および転移の阻害に使用するための抗体およびワクチン
CN103827144B (zh) 新的抗cxcr4抗体及其用于检测和诊断癌症的用途
JP2014512812A5 (https=)
JP6138780B2 (ja) 癌の検出および診断のための抗体i−3859の使用
Ni et al. CD24, a review of its role in tumor diagnosis, progression and therapy
US20220155320A1 (en) Cytokine profiling analysis
JPWO2019204057A5 (https=)
CN107850596A (zh) 用于检测组织浸润nk细胞的方法
JP2023113613A (ja) チェックポイント阻害薬のための予測末梢血バイオマーカー
US20210018508A1 (en) Igf-1r antibody and its use for the diagnosis of cancer
KR102350259B1 (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
CN116333137A (zh) 一种cd103抗体及其应用
JPWO2021067800A5 (https=)
Liu et al. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts
CN116940844A (zh) 新颖生物标志物及其用途
JP2025537826A (ja) 抗sirpa抗体についての効力予測バイオマーカー
CN116547301A (zh) 使用抗体进行的细胞表面mica和micb检测
BR112017022635B1 (pt) Anticorpo anti-igf-1r, kits, e métodos para a detecção in vitro ou ex vivo da presença e/ou localização de células tumorais expressando igf-1r em um indivíduo, para a detecção in vitro ou ex vivo da percentagem de células tumorais que expressam igf-1r em um indivíduo, para a determinação in vitro ou ex vivo do nível de expressão de igf-1r em células tumorais em um indivíduo, para a determinação in vitro ou ex vivo da pontuação de igf-1r de células tumorais ou de um tumor em um indivíduo, para determinar se um transtorno oncogênico é suscetível ao tratamento com uma droga de anticorpo tendo como alvo a via de igf-1r, para a determinação in vitro ou ex vivo da eficácia de um regime terapêutico conce(...)
WO2020101039A1 (ja) 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果判定
JPWO2023081818A5 (https=)